SciELO - Scientific Electronic Library Online

 
vol.73 número1Inmunodeficiencias primarias y linfomas de células BAvances recientes en los factores de riesgo, diagnóstico y tratamiento de la enfermedad linfoproliferativa post trasplante con infección por virus de Epstein-Barr índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

Links relacionados

  • No hay artículos similaresSimilares en SciELO

Compartir


Boletín médico del Hospital Infantil de México

versión impresa ISSN 1665-1146

Resumen

JIMENEZ-HERNANDEZ, Elva et al. Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis: response to HLH-04 treatment protocol. Bol. Med. Hosp. Infant. Mex. [online]. 2016, vol.73, n.1, pp.26-30. ISSN 1665-1146.  http://dx.doi.org/10.1016/j.bmhimx.2015.12.007.

Introduction:

Hemophagocytic syndrome, macrophage activation syndrome, reactive histiocytosis or hemophagocytic lymphohistiocytosis (HLH) represent a group of diseases whose common thread is reactive or neoplastic mononuclear phagocytic system cells and dendritic cell proliferation.

Clinical case:

We present a case of an HLH probably associated with Epstein-Barr virus (EBV) in a 4-year-old male patient treated with HLH-04 protocol. Viral etiology in HLH is well accepted. In this case, clinical picture of HLH was assumed secondary to EBV infection because IgM serology at the time of clinical presentation was the only positive factor in the viral panel.

Conclusions:

Diagnosis of HLH is the critical first step to successful treatment. The earlier it is identified, the less the tissue damage and reduced risk of multiple organ failure, which favors treatment response.

Palabras llave : Hemophagocytic lymphohistiocytosis; Hemophagocytic syndrome; Epstein-Barr virus; Protocol HLH-04.

        · resumen en Español     · texto en Inglés     · Inglés ( pdf )